AI Article Synopsis
- * After the second treatment, he developed fever and fatigue, with lab tests revealing heart damage and a biopsy confirming myocarditis as an immune-related adverse event.
- * Despite receiving high-dose corticosteroids, his condition deteriorated rapidly, resulting in his death five days later, highlighting the need for effective treatment options for severe myocarditis arising from cancer immunotherapy.
Article Abstract
A 59-year-old man with a high level of antinuclear antibody received nivolumab and ipilimumab plus chemotherapy for lung cancer. Two weeks after the second course, he was admitted with a fever and severe fatigue. Laboratory studies showed elevated markers of myocardial damage, and a myocardial biopsy showed inflammatory cell infiltration, damaged myocardial fibers. Myocarditis was diagnosed as an immune-related adverse event (irAE), and high-dose corticosteroids were initiated. However, his cardiac function rapidly worsened, and he died on the fifth day after admission. There is no established treatment strategy for fulminant myocarditis as an irAE, and the further exploration of viable treatment strategies is required.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208784 | PMC |
| http://dx.doi.org/10.2169/internalmedicine.0505-22 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!